-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Article source: Medical Cube Info
On April 19, Connoya announced that its new drug CMG901 (Claudin 18.
CMG901 is an antibody-drug conjugate targeting Claudin 18.
CMG901 is currently undergoing a dose escalation study in patients with solid tumors to evaluate the safety and tolerability of CMG901
Previously, Connoya has obtained FDA approval for CMG901 clinical trials in gastric cancer and gastroesophageal junction adenocarcinoma in the United States in March 2021, and received FDA orphan drug designation in April 2022